KSHV-specific antivirals targeting the protein-DNA interaction of the latency-associated nuclear antigen.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractThe Kaposi sarcoma-associated herpesvirus (KSHV) is an oncogenic human herpesviruses that is responsible for cancer, especially in immunosuppressed people, such as patients with AIDS. So far, there are no KSHV-specifc antiviral agents available. In this review, we provide an overview on one particular target-centered approach toward novel anti-KSHV drugs focusing on interfering with the molecular functions of the latency-associated nuclear antigen (LANA). This review focuses on attempts to interfere with the LANA-DNA interaction mediated by the C-terminal domain. We describe the drug discovery approaches chosen for this endeavor as well as molecular structures that were identified in this innovative concept toward novel and KSHV-specific antiherpesviral agents.
CitationFuture Med Chem. 2021 Jul;13(13):1141-1151. doi: 10.4155/fmc-2021-0059. Epub 2021 May 26.
AffiliationHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.
PublisherFuture Science Group
JournalFuture medicinal chemistry
The following license files are associated with this item:
- Creative Commons
- Reduction of Kaposi's Sarcoma-Associated Herpesvirus Latency Using CRISPR-Cas9 To Edit the Latency-Associated Nuclear Antigen Gene.
- Authors: Tso FY, West JT, Wood C
- Issue date: 2019 Apr 1
- Murine Gammaherpesvirus 68 Expressing Kaposi Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen (LANA) Reveals both Functional Conservation and Divergence in LANA Homologs.
- Authors: Gupta A, Oldenburg DG, Salinas E, White DW, Forrest JC
- Issue date: 2017 Oct 1
- Full-Length Isoforms of Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Accumulate in the Cytoplasm of Cells Undergoing the Lytic Cycle of Replication.
- Authors: Garrigues HJ, Howard K, Barcy S, Ikoma M, Moses AV, Deutsch GH, Wu D, Ueda K, Rose TM
- Issue date: 2017 Dec 15
- Kaposi's Sarcoma Herpesvirus Genome Persistence.
- Authors: Juillard F, Tan M, Li S, Kaye KM
- Issue date: 2016
- The Kaposi Sarcoma Herpesvirus Latency-associated Nuclear Antigen DNA Binding Domain Dorsal Positive Electrostatic Patch Facilitates DNA Replication and Episome Persistence.
- Authors: Li S, Tan M, Juillard F, Ponnusamy R, Correia B, Simas JP, Carrondo MA, McVey CE, Kaye KM
- Issue date: 2015 Nov 20